公开(公告)号：US20240016917A1

公开(公告)日：2024-01-18

申请号：US18005573

申请日：2022-04-12

Applicant: ACADEMIA SINICA

Inventor： Che MA ,  Chi-Huey WONG ,  Han-Yi HUANG

IPC: A61K39/215 ,  A61P31/04

CPC classification number: A61K39/215 ,  A61P31/04 ,  A61K2039/55505

Abstract: The present disclosure provides a glycoengineered SARS-CoV-2 spike protein which is capable of eliciting an enhanced immune response relative to a native spike protein of SARS-CoV-2 and its variants. The glycoengineered spike protein exposes the glycosylation sites and at the same time preserves the tertiary structure of the spike protein. The present disclosure therefore provides improved immunogens, vaccines, and methods for better prevention and treatment of the emerging coronavirus infections.

公开(公告)号：US20230302114A1

公开(公告)日：2023-09-28

申请号：US17998208

申请日：2021-05-07

Applicant: ACADEMIA SINICA

Inventor： Chi-Huey WONG ,  Hsin-Yu LIAO ,  Shih-Chi WANG ,  Yi-An KO ,  Kuo-I LIN ,  Che MA ,  Ting-Jen CHENG

IPC: A61K39/145 ,  C07K14/005 ,  A61P31/16

CPC classification number: A61K39/145 ,  A61P31/16 ,  C07K14/005 ,  A61K2039/575

Abstract: The present disclosure relates to a chimeric influenza virus hemagglutinin (HA) polypeptide, comprising one or more stem domain sequence, each having at least 60% homology with a stem domain consensus sequence of H1 subtype HA (H1 HA) and/or H5 subtype HA (H5 HA), fused with one or more globular head domain sequence, each having at least 60% homology with a globular head domain consensus sequence of H1 subtype HA (H1 HA) or H5 subtype HA (H5 HA).

公开(公告)号：US20170275389A1

公开(公告)日：2017-09-28

申请号：US15505763

申请日：2015-08-21

Applicant: ACADEMIA SINICA

Inventor： Chi-Huey WONG ,  Chung-Yi WU ,  Hsin-Yu LEE

IPC: C08B37/00 ,  A61K39/00 ,  C07K14/34 ,  A61K47/36 ,  C07K14/33

CPC classification number: C08B37/0024 ,  A61K39/0011 ,  A61K39/0016 ,  A61K47/36 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/555 ,  A61K2039/6037 ,  C07H3/06 ,  C07K14/33 ,  C07K14/34 ,  G01N2333/4728

Abstract: This disclosure includes an immunogenic composition containing (a) a glycan conjugate including a carrier and one or more glycans, wherein each of the one or more glycans is conjugated with the carrier through a linker, and optionally (b) an adjuvant. The one or more glycan is each a Globo H derivative.

公开(公告)号：US20170102387A1

公开(公告)日：2017-04-13

申请号：US15210565

申请日：2016-07-14

Applicant: Academia Sinica

Inventor： Chi-Huey WONG ,  Jim-Min FANG ,  Yih-Shyun Edmund CHENG ,  Jiun-Jie SHIE

IPC: G01N33/569

CPC classification number: G01N33/56983 ,  A61K31/665 ,  A61K31/683 ,  C07F9/6552 ,  G01N2333/11

Abstract: Methods and compositions for detection of drug resistant pathogens and treatment against infections thereof are provided. Methods for detection of oseltamivir-resistant influenza viruses by competitive binding assays utilizing non-oseltamivir influenza virus neuraminidase inhibitors and oseltamivir carboxylate are provided. Influenza virus neuraminidase inhibitors coupled to sensors and useful for employment in the methods of the invention are disclosed. Novel phosphonate compounds active as neuraminidase inhibitors against wild-type and oseltamivir-resistant influenza strains of H1N1, H5N1 and H3N2 viruses are disclosed. An enantioselective synthetic route to preparation of these phosphonate compounds via sialic acid is provided.

公开(公告)号：US20160289340A1

公开(公告)日：2016-10-06

申请号：US15011543

申请日：2016-01-30

Applicant: Academia Sinica

Inventor： Chi-Huey WONG ,  Tsui-Ling HSU ,  Yi-Wei LOU ,  Chih-Wei LIN ,  Shih-Chi YEH ,  Chung-Yi WU ,  Han-Chung WU ,  Han-Chung WU

IPC: C07K16/44

CPC classification number: C07K16/44 ,  A61K2039/505 ,  C07K16/18 ,  C07K16/3053 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  G01N33/57407 ,  G01N2800/52

Abstract: Pharmaceutical composition comprising antibodies or antigen binding fragments thereof that bind to globo H, SSEA3, and SSEA-4 are disclosed herein, as well as methods of use thereof. Methods of use include, without limitation, cancer therapies and diagnostics. The antibodies of the disclosure can bind to certain cancer cell surfaces. Exemplary targets of the antibodies disclosed herein can include carcinomas, such as those in brain, skin, bone, lungs, breast, esophagus, stomach, liver, bile duct, pancreas, colon, kidney, cervical, ovarian, and/or prostate cancer.

Abstract translation: 本文公开了包含与globo H，SSEA3和SSEA-4结合的抗体或其抗原结合片段的药物组合物及其使用方法。 使用的方法包括但不限于癌症治疗和诊断。 本公开的抗体可以结合某些癌细胞表面。 本文公开的抗体的示例性靶标可以包括癌，例如脑，皮肤，骨，肺，乳腺，食道，胃，肝，胆管，胰腺，结肠，肾，子宫颈，卵巢和/或前列腺癌中的那些。

公开(公告)号：US20160102116A1

公开(公告)日：2016-04-14

申请号：US14847835

申请日：2015-09-08

Applicant: Academia Sinica

Inventor： Chi-Huey WONG ,  Alice L. YU ,  Kun-Hsien LIN ,  Tai-Na WU

IPC: C07H15/18 ,  A61K39/39

CPC classification number: C07H15/18 ,  A61K31/7032 ,  A61K39/39 ,  A61K2039/55511 ,  A61K2039/585 ,  C07H15/04 ,  C07H17/02

Abstract: Glycosphingolipids (GSLs) compositions and methods for iNKT-independent induction of chemokines are disclosed.

Abstract translation: 公开了用于iNKT非依赖性诱导趋化因子的糖鞘糖脂（GSL）组合物和方法。

公开(公告)号：US20150344544A1

公开(公告)日：2015-12-03

申请号：US14723297

申请日：2015-05-27

Applicant: Academia Sinica

Inventor： Chi-Huey WONG ,  Chung-Yi Wu ,  Che Ma

IPC: C07K16/00 ,  C07K16/28 ,  C07K16/30 ,  C07K16/24 ,  C07K16/10 ,  A61K39/42 ,  A61K39/395 ,  A61K45/06 ,  C07K16/32

CPC classification number: C12P19/14 ,  A61K39/3955 ,  A61K39/42 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/1018 ,  C07K16/18 ,  C07K16/241 ,  C07K16/2887 ,  C07K16/2896 ,  C07K16/30 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/41 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  C12N9/24 ,  C12Y302/01 ,  C12Y302/01051 ,  Y02A50/412 ,  Y02A50/466

Abstract: The present disclosure relates to glycoproteins, particularly monoclonal antibodies, comprising a glycoengineered Fc region, wherein said Fc region comprises an optimized N-glycan having the structure of Sia2(α2-6)Gal2GlcNAc2Man3GlcNAc2. The glycoengineered Fc region binds FcγRIIA or FcγRIIIA with a greater affinity, relative to comparable monoclonal antibodies comprising the wild-type Fc region. The monoclonal antibodies of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer, autoimmune, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

Abstract translation: 本公开涉及包含糖工程化Fc区的糖蛋白，特别是单克隆抗体，其中所述Fc区包含具有Sia2（α2-6）Gal2GlcNAc2Man3GlcNAc2结构的优化的N-聚糖。 相对于包含野生型Fc区域的可比较的单克隆抗体，糖工程化Fc区域以更高的亲和力结合FcγRIIA或FcγRIIIA。 本发明的单克隆抗体特别可用于预防，治疗或改善与需要由FcγR介导的效应细胞功能（例如，ADCC）增强的功效的疾病，病症或感染相关的一种或多种症状，例如， 癌症，自身免疫性，感染性疾病，以及提高其作用由ADCC介导的治疗性抗体的治疗功效。

公开(公告)号：US20150309041A1

公开(公告)日：2015-10-29

申请号：US14698660

申请日：2015-04-28

Applicant: Academia Sinica

Inventor： Chi-Huey WONG ,  Jim-Min FANG ,  Jiun-Jie SHIE

IPC: G01N33/58 ,  C07D311/02 ,  C07D309/14 ,  C07F5/02

CPC classification number: G01N33/582 ,  C07D309/14 ,  C07D311/02 ,  C07F5/027 ,  C07K7/08 ,  G01N21/64 ,  G01N2333/924 ,  G01N2458/30

Abstract: Provided are azido-BODIPY compounds of formula (I), cyclooctyne-based fluorogenic probes of formula (IV), and activity-based probes of formula (VI). These compounds undergo azide alkyne cycloadditions (AAC) with to form triazolyl products. The provided compounds are useful for detection and imaging of alkyne-, or azide-containing molecules. Methods for detection and imaging biomolecules using compounds of the present disclosure are disclosed.

Abstract translation: 提供式（I）的叠氮基-BODIPY化合物，式（IV）的基于环辛烯的荧光探针和式（VI）的基于活性的探针。 这些化合物经历叠氮炔环加成（AAC）以形成三唑基产物。 所提供的化合物可用于检测和成像含炔或叠氮化物的分子。 公开了使用本公开的化合物检测和成像生物分子的方法。

公开(公告)号：US20250082744A1

公开(公告)日：2025-03-13

申请号：US18927447

申请日：2024-10-25

Applicant: ACADEMIA SINICA

Inventor： Chi-Huey WONG ,  Hsin-Yu LIAO ,  Shih-Chi WANG ,  Yi-An KO ,  Kuo-I LIN ,  Che MA ,  Ting-Jen CHENG

IPC: A61K39/145 ,  A61K39/00 ,  A61P31/16 ,  C07K14/005

Abstract: The present disclosure relates to a chimeric influenza virus hemagglutinin (HA) polypeptide, comprising one or more stem domain sequence, each having at least 60% homology with a stem domain consensus sequence of H1 subtype HA (H1 HA) and/or H5 subtype HA (H5 HA), fused with one or more globular head domain sequence, each having at least 60% homology with a globular head domain consensus sequence of H1 subtype HA (H1 HA) or H5 subtype HA (H5 HA).

公开(公告)号：US20230279080A1

公开(公告)日：2023-09-07

申请号：US18146873

申请日：2022-12-27

Applicant: ACADEMIA SINICA

Inventor： Kuo-I LIN ,  Chi-Huey WONG ,  Szu-Wen WANG ,  Yi-Hsuan CHANG

IPC: C07K16/10 ,  G01N33/569 ,  A61K45/06

CPC classification number: C07K16/10 ,  A61K45/06 ,  G01N33/56983 ,  C07K2317/31 ,  C07K2317/41 ,  C07K2317/92 ,  G01N2333/165 ,  G01N2469/10

Abstract: The present disclosure relates to an antibody or antigen-binding fragment thereof that is specific for a spike protein of SARS-CoV-2. The present disclosure also relates to a pharmaceutical composition for treating and/or preventing diseases and/or disorders caused by a coronavirus in a subject in need thereof, and a method for detecting a coronavirus in a sample.